Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Eli Lilly stated on Thursday that it intends to file for regulatory approval of retatrutide, its next-generation obesity treatment, during the first quarter of 2027. The company had previously indicated it might submit an application as early as that year, but determined it requires additional time to compile and verify manufacturing and quality-control data required by regulatory authorities before proceeding with the filing.
The pharmaceutical company reported positive results from two separa